Cargando…
Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
Salvage chemotherapy for refractory metastatic colorectal cancer using trifluridine/tipiracil (FTD/TPI) and regorafenib has shown survival benefits. We evaluated the antitumor effects of FTD or FTD/TPI combined with regorafenib in vitro and in vivo. SW620, HCT 116, and HT-29 human colorectal cancer...
Autores principales: | Matsuoka, Kazuaki, Nakagawa, Fumio, Tanaka, Nozomu, Okabe, Hiroyuki, Matsuo, Kenichi, Takechi, Teiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213129/ https://www.ncbi.nlm.nih.gov/pubmed/30257515 http://dx.doi.org/10.3390/ijms19102915 |
Ejemplares similares
-
Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression
por: Matsuoka, Kazuaki, et al.
Publicado: (2018) -
Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts
por: Suzuki, Norihiko, et al.
Publicado: (2016) -
Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer
por: Suzuki, Norihiko, et al.
Publicado: (2017) -
Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer
por: Suzuki, Norihiko, et al.
Publicado: (2021) -
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)